Neuropharmacology and therapeutic potential of cannabinoids

Addiction Biology

Volumn 5, Issue 1, 2000, Pages 37-46

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AJULEMIC ACID; ANANDAMIDE; ANTIEMETIC AGENT; APPETITE STIMULANT; CANNABINOID; CANNABINOID RECEPTOR; DEXANABINOL; DRONABINOL; DRUG RECEPTOR; L 759633; L 759656; LIGAND; METHYLAMINE; NABILONE; RIMONABANT; UNCLASSIFIED DRUG;

AMNESIA; ANALGESIA; APPETITE DISORDER; ASTHMA; COGNITIVE DEFECT; DRUG ANTAGONISM; DRUG BINDING; GLAUCOMA; HUMAN; IMMUNOCOMPETENT CELL; MULTIPLE SCLEROSIS; NERVE CELL; NEUROPHARMACOLOGY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SPINE INJURY; VOMITING;

EID: 0033965479     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556210071252     Document Type: Review

References (110)

1. 1. Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 1988;36:189-261.
2. 2 receptors. Pharmacol Ther 1997;74: 129-80.
3. 3. Pertwee RG. Advances in cannabinoid receptor pharmacology. In: Brown DT, editor. Cannabis. Amsterdam: Harwood Academic Publishers; 1998, pp. 125-74.
4. 8 linkage to the CB1 receptor. J Neurosci 1997;17:5327-33.
5. 5. Matsuda LA. Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 1997;11:143-66.
6. 6. Gessa GL, Mascia MS, Casu MA, Carta G. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR141716A. Eur J Pharmacol 1997;327:R1-2.
7. 7. Gessa GL, Casu MA, Carta G, Mascia MS. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur J Pharmacol 1998; 355:119-24.
8. 8. Chan PKY, Yung W-H. Occlusion of the pre-synaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium. Neurosci Lett 1998;249:57-60.
9. 9. Cadogan A-K, Alexander SPH, Boyd EA, Kendall DA. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem 1997;69: 1131-7.
10. 10. Gifford AN, Samiian L, Gatley SJ, Ashby CR. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Eur J Pharmacol 1997;324:187-92.
11. 1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedeberg's Arch Pharmacol 1997;356:583-9.
12. 12. Shen M, Piser TM, Seybold VS, Thayer SA. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996;16:4322-34.
13. 13. Shen M, Thayer SA. The cannabinoid agonist WIN55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res 1998; 783:77-84.
14. 14. Szabo B, Dörner L, Pfreundtner C, Nörenberg W, Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 1998;85: 395-403.
15. 15. Di Marzo V, Fontana A, Cadas H et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372: 686-91.
16. 16. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 1997;17: 1226-42.
17. 17. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 1997;322: 671-7.
18. 18. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB. Accumulation of N-arachidonoyl-ethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 1997;69:631-8.
19. 19. Di Marzo V. "Endocannabinoids" and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998;1392: 153-75.
20. 20. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-7.
21. 21. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci USA 1997;94: 2238-42.
22. 22. Thomas EA, Cravatt BF, Danielson PE, Gilula NB, Sutcliffe JG. Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J Neurosci Res 1997;50:1047-52.
23. 23. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 1998;422:69-73.
24. 24. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997;277:1094-7.
25. 25. Barth F. Cannabinoid receptor agonists and antagonists. Exp Opin Ther Patents 1998;8: 301-13.
26. 26. Mechoulam R, Ben-Shabat S, Hanus L et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50: 83-90.
27. 2 receptors. Mol Pharmacol 1995;48:443-50.
28. 28. Gareau Y, Dufresne C, Gallant M et al. Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg Med Chem Lett 1996;6:189-94.
29. 9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 1996;271:9902-5.
30. 30. Shire D, Calandra B, Rinaldi-Carmona M et al. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1996;1307:132-6.
31. 31. Khanolkar AD, Abadji V, Lin S et al. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 1996;39: 4515-19.
32. 32. Ben-Shabat S, Fride E, Sheskin T et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998;353: 23-31.
33. 2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 1999;126:665-72.
34. 34. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996;278:989-99.
35. 35. Rhee M-H, Vogel Z, Barg J et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 1997; 40:3228-33.
36. 36. Felder CC, Joyce KE, Briley EM et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 1998;284:291-7.
37. 37. Rinaldi-Carmona M, Barth F, Millan J et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998;284:644-50.
38. 38. Bouaboula M, Perrachon S, Milligan L et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. J Biol Chem 1997;272: 22330-9.
39. 2 receptors. Br J Pharmacol 1998;124:619-22.
40. 9-tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. Eur J Pharmacol 1997;323:R3-4.
41. 35S]GTP-γS autoradiography in rat brain. J Neurosci 1996;16:8057-66.
42. 8-THC-11-oic acid (CT3) in mice. Life Sci 1998;63:161-8.
43. 43. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 1997;40:659-67.
44. 44. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995;92:3376-80.
45. 45. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-81.
46. 46. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998;63:PL113-17.
47. 47. Simiand J, Keane M, Keane PE, Soubrié P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998;9:179-81.
48. 48. Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelet M, Soubrié P, Le Fur G. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997;132: 104-6.
49. 49. Pertwee RG. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Pharm Sci 1997;3:539-545.
50. 50. Morgan DR, ed. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers, 1997.
51. 51. Zeltser R, Seltzer Z, Eisen A, Feigenbaum JJ, Mechoulam R. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain 1991;47:95-103.
52. 52. Yoles E, Belkin M, Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces short-and long-term neuroprotection after optic nerve axotomy. J Neurotrauma 1996;13:49-57.
53. 53. Gallily R, Yamin A, Waksmann Y et al. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), α nonpsychotropic cannabinoid. J Pharmacol Exp Ther 1997;283: 918-24.
54. 6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett 1993;162:43-5.
55. 55. Eshhar N, Striem S, Biegon A. HU-211, a nonpsychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 1993;5:237-40.
56. 56. Bar-Joseph A, Berkovitch Y, Adamchik J, Biegon A. Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol Chem Neuropathol 1994;23:125-35.
57. 57. Belayev L, Bar-Joseph A, Adamchik J, Biegon A. HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats. Mol Chem Neuropathol 1995;25:19-33.
58. 58. Shohami E, Novikov M, Mechoulam R. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma 1993;10:109-19.
59. 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211. Brain Res 1995; 685:1-11.
60. 60. Bass R, Engelhard D, Trembovler V, Shohami E. A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. J Infect Dis 1996;173:735-8.
61. 61. Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci USA 1989;86:9584-7.
62. 2+ influx through the N-methyl-D-aspartate receptor ion channel by the nonpsychoactive cannabinoid HU-211. Brain Res 1993;622:79-85.
63. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998;95:8268-73.
64. 64. Skaper SD, Buriani A, Dal Toso R et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 1996;93:3984-9.
65. 65. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998;54: 459-62.
66. 9-tetrahydrocannabinol. J Neurosci 1998;18: 5322-32.
67. 9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998; 436:6-10.
68. 68. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986;38:1-20.
69. 69. Paton WDM, Pertwee RG. The actions of cannabis in man. In: Mechoulam R, editor. Marijuana. New York: Academic Press; 1973, pp. 287-333.
70. 70. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Res 1995;15: 277-81.
71. 71. Paton WDM, Pertwee RG, Tylden E. Clinical aspects of cannabis action. In: Mechoulam R, editor. Marijuana. New York: Academic Press; 1973, pp. 335-65.
72. 72. Miller LL. Marijuana: acute effects on human memory. In: Agurell S, Dewey WL, Willette RE, editors. The cannabinoids: chemical, pharmacologic and therapeutic aspects. Orlando: Academic Press; 1984, pp. 21-46.
73. 73. Rosenkrantz H. Cannabis components and responses of neuroendocrine reproductive targets: an overview. In: Harvey DJ, editor. Marihuana '84. Oxford: IRL Press; 1985, pp. 457-505.
74. 74. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;38:151-78.
75. 75. Jones RT. Cardiovascular effects of cannabinoids. In: Harvey DJ, editor. Marihuana '84. Oxford: IRL Press; 1985, pp. 325-34.
76. 76. Jones RT. Cannabis tolerance and dependence. In: Fehr KO, Kalant H, editors. Cannabis and health hazards. Toronto: Addiction Research Foundation; 1983, pp. 617-89.
77. 77. Jones RT, Benowitz N. The 30-day trip - clinical studies of cannabis tolerance and dependence. In: Braude MC, Szara S, editors. Pharmacology of marihuana. New York: Raven Press; 1976, pp. 627-42.
78. 78. Pertwee RG. Tolerance to and dependence on psychotropic cannabinoids. In: Pratt JA, editor. The biological bases of drug tolerance and dependence. London: Academic Press; 1991, pp. 231-63.
79. 79. Aceto MD, Scates SM, Lowe JA, Martin BR. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 1995;282:R1-2.
80. 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996;278:1290-5.
81. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 1995;280:R13-15.
82. 82. Lichtman AH, Wiley JL, LaVecchia KL et al. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. Eur J Pharmacol 1998;357:139-48.
83. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1998;285:1150-6.
84. 84. Rubino T, Patrini G, Massi P et al. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998;285:813-19.
85. 85. Sherman MP, Campbell LA, Gong H, Roth MD, Tashkin DP. Antimicrobial and respiratory burst characteristics of pulmonary alveolar macrophages recovered from smokers of marijuana alone, smokers of tobacco alone, smokers of marijuana and tobacco, and nonsmokers. Am Rev Resp Dis 1991;144:1351-6.
86. 8-tetrahydrocannabinol in two isolated tissue preparations. Eur J Pharmacol 1996; 315:195-201.
87. 35S]thio)triphosphate binding in rat brain membranes. Life Sci 1996;59:659-68.
88. 15S]thio]triphosphate binding. Proc Natl Acad Sci USA 1995;92:7242-6.
89. 9-tetrahydrocannabinol-induced analgesia. Brain Res 1992;578:8-12.
90. 90. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1991;258:517-23.
91. 91. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 1996;276:585-93.
92. 92. Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 1998;242: 33-6.
93. 93. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998;75:111-19.
94. 94. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol. Exp Ther 1992;262:10-18.
95. 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 1996;279: 608-16.
96. 96. Pertwee RG. In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. In: Murphy L, Bartke A, editors. Marijuana/ cannabinoids. Neurobiology and neurophysiology. Boca Raton: CRC Press; 1992, pp. 165-218.
97. 97. Richter A, Löscher W. ( + )-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol 1994;264:371-7.
98. 98. Pertwee RG. Evidence for the presence of CB, cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB, cannabinoid receptors. Life Sci 1999;65:597-605.
99. 99. Pertwee RG. Prescribing cannabinoids for multiple sclerosis: current issues. CNS Drugs 1999;11:327-34.
100. 9-tetrahydrocannabinol. Psychopharmacologia 1973;33: 53-70.
101. 9-tetrahydrocannabinol. Gen Pharmacol 1983; 14:247-52.
102. 102. Welburn PJ, Starmer GA, Chesher GB, Jackson DM. Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacology 1976;46: 83-5.
103. 9-tetrahydrocannabinol in man. Eur J Pharmacol 1974;28:172-7.
104. 104. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology 1982;76:245-50.
105. 105. Mattes RD, Shaw LM, Edling-Owens J, Engelman K, ElSohly MA. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav 1993;44:745-7.
106. 106. Mattes RD, Engelman K, Shaw LM, ElSohly MA. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 1994;49:187-95.
107. 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996;34:446-52.
108. 9-tetrahydrocannabinol. J Pharm Pharmacol 1976;28:86.
109. 9-tetrahydrocannabinol in healthy and asthmatic subjects. Am Rev Resp Dis 1977;115: 57-65.
110. 1-tetrahydrocannabinol administered by aerosol to asthmatic patients. Thorax 1976;31:720-3.